Mdxhealth Third-Quarter Revenue Flat at $22.7 Million With Net Loss of $12.3 Million
Mdxhealth, the urology-focused precision diagnostics company, announced financial results on November 12, 2026 for the third quarter ended September 30, 2026. The company said revenue from continuing operations was $22.7 million, flat compared with the prior-year period.
Operating loss was $8.1 million, compared with $4.4 million in the third quarter of 2025, primarily due to increased operating expenses related to the ExoDx acquisition, the company said.
Net loss was $12.3 million, an increase of 26 percent over the prior-year period. Adjusted EBITDA was negative $6.3 million, compared with negative $0.9 million a year earlier.
Revenue in the third quarter of 2026 and 2025 was comprised of 79 percent and 92 percent from tissue-based tests, respectively, the company said.
For the nine months ended September 30, 2026, revenue increased 9 percent to $73.8 million, compared with $67.7 million a year earlier. Results exclude Resolve mdx, which has been discontinued and accounted for as a discontinued operation.
All figures are from Mdxhealth's own earnings release distributed via GlobeNewswire.
Related: MDxHealth preliminary third-quarter revenue report
Source: Mdxhealth
Published by GSM · USA (original Chinese edition)
Photo: 医学诊断实验室内的分析仪与技术人员。／Analyzers and technicians in a medical diagnostics laboratory.（Esculab，CC0，Wikimedia Commons）
